Hematologic malignancy cells

Hematologic malignancy cells represent a diverse group of cancerous cells originating from the blood-forming tissues, such as the bone marrow, or the cells of the immune system, including leukemias, lymphomas, and multiple myelomas [National Cancer Institute, 2024]. These cells are characterized by the clonal expansion of hematopoietic cells that have escaped normal regulatory mechanisms governing cell growth and differentiation [StatPearls, "Hematologic Malignancies," 2023]. This entry is considered 'incorrect' as a target because it refers to an entire cellular population or disease state rather than a specific protein, enzyme, or receptor molecule. Therapeutic strategies aimed at these cells involve targeting specific molecular drivers or surface markers, such as the BCR-ABL tyrosine kinase in chronic myeloid leukemia or CD20 in B-cell lymphomas [PubMed, PMC7355135]. Understanding the biological heterogeneity of these cells is essential for the application of targeted therapies and immunotherapies, such as CAR-T cell therapy, which seek to eradicate the malignant population while preserving healthy hematopoietic function.

Other names

Blood cancer cellsLiquid tumor cellsMalignant hematopoietic cellsLeukemia cellsLymphoma cellsMultiple myeloma cells

Drugs do not target these cells as a single molecule; instead, they target specific surface antigens (e.g., CD20, CD19), intracellular enzymes (e.g., BCR-ABL, BTK), or apoptotic pathways (e.g., BCL-2) within the cells to induce cell death or inhibit proliferation.